The Analysis Study of Effects of Metformin on Ovarian Cancer : A Comprehensive Systematic Review
Keywords:
Ovarian cancer, metformin, chemotherapy, therapy, effectAbstract
Background: Ovarian cancer is one of the 10 most common cancers in women, with an estimated 295,414 new cases and 184,799 deaths worldwide in 2018. Metformin also activates the adenosine monophosphate-activated protein kinase pathway via liver kinase B1, which is a key gate pathway related to inhibition of subsequent tumor growth biomarkers, insulin signaling cascade, and cell cycle regulatory pathways. The aim: The aim of this study to show about effects of metformin on ovarian cancer. Methods: By the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020, this study was able to show that it met all of the requirements. Result: Eight publications were found to be directly related to our ongoing systematic examination after a rigorous three-level screening approach. Subsequently, a comprehensive analysis of the complete text was conducted, and additional scrutiny was given to these articles. Conclusion: Long-term metformin use reduced all-cause mortality, but not cancer-specific survival (CSS) in ovarian cancer. Whether metformin itself reduces deaths because of ovarian cancer requires further investigation.
References
Wen KC, Sung PL, Wu ATH, Chou PC, Lin JH, Huang CYF, et al. Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer. J Ovarian Res. 2020;13(1):1–13.
Garrido MP, Salvatierra R, Valenzuela-Valderrama M, Vallejos C, Bruneau N, Hernández A, et al. Metformin reduces ngf-induced tumour promoter effects in epithelial ovarian cancer cells. Pharmaceuticals. 2020;13(10):1–20.
Noren Hooten N, Martin-Montalvo A, Dluzen DF, Zhang Y, Bernier M, Zonderman AB, et al. Metformin-mediated increase in DICER1 regulates microRNA expression and cellular senescence. Aging Cell. 2016;15(3):572–81.
Zou G, Bai J, Li D, Chen Y. Effect of metformin on the proliferation, apoptosis, invasion and autophagy of ovarian cancer cells. Exp Ther Med. 2019;2086–94.
Tossetta G. Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings. Int J Mol Sci. 2022;23(21).
Taylor SE, Chan DK, Yang D, Bruno T, Lieberman R, Siddiqui J, et al. Shifting the Soil: Metformin Treatment Decreases the Protumorigenic Tumor Microenvironment in Epithelial Ovarian Cancer. Cancers (Basel). 2022;14(9).
Febbraro T, Lengyel E, Romero IL. Old drug, new trick: Repurposing metformin for gynecologic cancers? Gynecol Oncol [Internet]. 2014 Dec;135(3):614–21. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0090825814013717
Imai A, Ichigo S, Matsunami K, Takagi H, Yasuda K. Clinical benefits of metformin in gynecologic oncology (Review). Oncol Lett. 2015;10(2):577–82.
Park JY, Lim MC, Baek MH, Park YH, Kim S. Impact of metformin on survival outcome in ovarian cancer: A nationwide population-based cohort study. J Gynecol Oncol. 2021;32(4).
Urpilainen E, Marttila M, Hautakoski A, Arffman M, Sund R, Ilanne-Parikka P, et al. Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: A retrospective cohort study. BMC Cancer. 2018;18(1):1–9.
Bar D, Lavie O, Stein N, Feferkorn I, Shai A. The effect of metabolic comorbidities and commonly used drugs on the prognosis of patients with ovarian cancer. Eur J Obstet Gynecol Reprod Biol [Internet]. 2016;207:227–31. Available from: http://dx.doi.org/10.1016/j.ejogrb.2016.09.005
Wang SB, Lei KJ, Liu JP, Jia YM. Continuous use of metformin can improve survival in type 2 diabetic patients with ovarian cancer. Med (United States). 2017;96(29):1–6.
Shah MM, Erickson BK, Matin T, McGwin G, Martin JY, Daily LB, et al. Diabetes mellitus and ovarian cancer: More complex than just increasing risk. Gynecol Oncol. 2014;135(2):273–7.
Broekman KE, Hof MAJ, Touw DJ, Gietema JA, Nijman HW, Lefrandt JD, et al. Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer. Invest New Drugs. 2020;38(5):1454–62.
Micha JP, Rettenmaier MA, Bohart RD, Goldstein BH. A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma. J Gynecol Oncol. 2023;34(2):1–9.
Brown JR, Chan DK, Shank JJ, Griffith KA, Fan H, Szulawski R, et al. Phase II clinical trial of metformin as a cancer stem cell–targeting agent in ovarian cancer. JCI Insight. 2020;5(11):0–12.
Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, et al. Repurposing metformin for cancer treatment: Current clinical studies. Oncotarget. 2016;7(26):40767–80.
Hua Y, Zheng Y, Yao Y, Jia R, Ge S, Zhuang A. Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing. J Transl Med [Internet]. 2023;21(1):1–20. Available from: https://doi.org/10.1186/s12967-023-04263-8
Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife. 2014;2014(3):1–18.
Ahmed MF, Kanaan G, Mostafa JA. The Role of Metformin in Ovarian Cancer: Does Metformin Increase Survival in Ovarian Neoplasm? Cureus. 2021;13(2).
Almeida-Nunes DL, Silvestre R, Dinis-Oliveira RJ, Ricardo S. Enhancing Immunotherapy in Ovarian Cancer: The Emerging Role of Metformin and Statins. Int J Mol Sci. 2024;25(1).
Worzfeld T, von Strandmann EP, Huber M, Adhikary T, Wagner U, Reinartz S, et al. The unique molecular and cellular microenvironment of Ovarian cancer. Front Oncol. 2017;7(FEB).
Guo M, Shang X, Guo D. Metformin Use and Mortality in Women with Ovarian Cancer: An Updated Meta-Analysis. Int J Clin Pract. 2022;2022:9592969.
Yao K, Zheng H, Li T. Association Between Metformin Use and the Risk, Prognosis of Gynecologic Cancer. Front Oncol. 2022;12(July).
He XK, Su TT, Si JM, Sun LM. Metformin is associated with slightly reduced risk of colorectal cancer and moderate survival benefits in diabetes mellitus a meta-analysis. Med (United States). 2016;95(7):e2749.
Wu L, Zhou B, Oshiro-Rapley N, Li M, Paulo JA, Webster CM, et al. An Ancient, Unified Mechanism for Metformin Growth Inhibition in C. elegans and Cancer. Cell [Internet]. 2016 Dec;167(7):1705-1718.e13. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0092867416316671
Published
Issue
Section
License
Copyright (c) 2024 Innesti Nur Fetana, Faisal Yoebel (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
